VERTEX PHARMACEUTICALS INC / MA 8-K

What Happened

• Vertex Pharmaceuticals filed a Form 8-K reporting that on April 28, 2026, director Suketu Upadhyay informed the Board he will not stand for re‑election at the Company’s 2026 annual meeting. Mr. Upadhyay was recently named the forthcoming Chief Financial Officer of Incyte Corporation and will remain on Vertex’s Board until the 2026 Annual Meeting. The Company announced the Board intends to reduce its size to ten members following his departure. The filing was made on April 29, 2026 under Item 5.02.

Key Details

• Date of notice: April 28, 2026; Form 8-K filed April 29, 2026.
• Reason given: scheduling conflicts related to his new role at Incyte; no disagreement with Vertex on operations, policies, or practices.
• Governance change: Board plans to reduce size to ten members after his departure.
• Proxy impact: Mr. Upadhyay has been removed as a nominee from the Company’s proxy materials for the 2026 Annual Meeting; previously submitted proxies remain valid except with respect to his re‑election, and the slate of other nominees is unchanged.

Why It Matters

• This is a governance-level change investors should note: a current director with recent finance leadership ties is leaving to become Incyte’s CFO, and the Board will shrink by one seat.
• The company states the departure is amicable and due to scheduling conflicts, suggesting no operational or policy disputes.
• Shareholders should be aware the proxy materials were amended to remove Mr. Upadhyay and that they can still vote their proxies on the remaining nominees and other matters at the 2026 Annual Meeting.